



ASX ANNOUNCEMENT

Investor Briefing Invitation

MELBOURNE, Australia (27 March 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has today released an ASX announcement and investor presentation relating to the FebriDx® CLIA waiver clearance and the completion of a Placement with a Share Purchase Plan to follow.

The Company will host a webinar on Tuesday, 31 March 2026 at 9.00am (AEDT) to discuss the announcements. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_rgpFV6_mTI6SnayhDT80Hg

Once the registration form is completed, investors will receive a confirmation email with details on how to access the meeting.

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598